2014 PERSIST-1 Trial is now recruiting for Phase 3

June 18, 2014

Clinical Trial Alert

A randomized, controlled Phase 3 study of oral Pacritinib vs. best available therapy for patients with myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis is anticipated to be closing soon. If you, or someone you know, is interested in participating in this study, click here for more information via ClinicalTrials.gov and/or contact Gordon Thomson at gthomson@ockham.com and indicate PERSIST-1 in the subject line, or call +44 (0) 131-440-6441.

As with any medical decision, you should discuss participation in this or any clinical trial with your physician and family. There are pros and cons to any medical study.